首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Clinical And Molecular Hepatology

Clinical And Molecular Hepatology杂志,由Korean Association for the Study of the Liver出版,于2012年创刊,4 issues/year,出版语言English,ISSN:2287-2728,E-ISSN:2287-285X。

投稿咨询
Clinical And Molecular Hepatology
Clinical And Molecular Hepatology
Clinical And Molecular Hepatology
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
21.7
CiteScore
28.1
期刊收录
SCI、SCIE

Clinical And Molecular Hepatology(中文译名:《临床和分子肝病学》),ISSN:2287-2728,EISSN:2287-285X,是Korean Association for the Study of the Liver出版的国际性学术期刊,创刊于2012年,以4 issues/year形式稳定发行,2026年总发文量约84篇。该刊采用OA开放访问,学科归属为Medicine - Hepatology。该刊是医学、胃肠肝病学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达21.7,2025年期刊CiteScore为28.1,2025年期刊自引率约6.5%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Clinical And Molecular Hepatology长期聚焦医学、胃肠肝病学及相关产业的技术应用前沿,平均审稿周期10 Weeks,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、胃肠肝病学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,South KoreaUSA、Japan、CHINA MAINLAND、India、Italy、Greece等为核心发文国家与地区;YONSEI UNIVERSITYSEOUL NATIONAL UNIVERSITY (SNU)、SUNGKYUNKWAN UNIVERSITY (SKKU)、CATHOLIC UNIVERSITY OF KOREA、SOONCHUNHYANG UNIVERSITY、KOREA UNIVERSITY、HALLYM UNIVERSITY等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
GASTROENTEROLOGY & HEPATOLOGY 胃肠肝病学
1区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
GASTROENTEROLOGY & HEPATOLOGY 胃肠肝病学
1区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
GASTROENTEROLOGY & HEPATOLOGY 胃肠肝病学
2区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:GASTROENTEROLOGY & HEPATOLOGY SCIE Q1 6 / 153

96.4

学科:GASTROENTEROLOGY & HEPATOLOGY SCIE Q1 8 / 153

95.1

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:GASTROENTEROLOGY & HEPATOLOGY SCIE Q1 6 / 143

96.2

学科:GASTROENTEROLOGY & HEPATOLOGY SCIE Q1 11 / 143

92.66


中国学者近期发文

1
Letter to the editor on Genome-wide interaction study with BMI identifies CYP7A1 and GIPR as genetic modulators of MASL

Author:Zheng, Sheng

Journal: CLINICAL AND MOLECULAR HEPATOLOGY. 2026; Vol. 32, Issue 2, pp. e170-e171. DOI: 10.3350/cmh.2025.0656

2
Letter to the editor on Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosi

Author:Zheng, Bo; Wang, Lizhou

Journal: CLINICAL AND MOLECULAR HEPATOLOGY. 2026; Vol. 32, Issue 2, pp. e141-e143. DOI: 10.3350/cmh.2025.0521

3
Reply to correspondence on Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation stud

Author:Yao, Xingyu

Journal: CLINICAL AND MOLECULAR HEPATOLOGY. 2026; Vol. 32, Issue 2, pp. e267-e268. DOI: 10.3350/cmh.2025.0892

4
Letter to the editor on Glucagon-like peptide 1 receptoragonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation stud

Author:Yao, Xingyu

Journal: CLINICAL AND MOLECULAR HEPATOLOGY. 2026; Vol. 32, Issue 2, pp. e165-e166. DOI: 10.3350/cmh.2025.0620

5
Metabolic dysfunction-associated steatotic liver disease: On track to become the dominant etiology of hepatocellular carcinoma: Reply to correspondence on Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidatio

Author:Xu, Jian; Zhang, Wei; Wu, Guo; Li, Jingdong

Journal: CLINICAL AND MOLECULAR HEPATOLOGY. 2026; Vol. 32, Issue 2, pp. e257-e261. DOI: 10.3350/cmh.2025.0853

6
Critical flaws in the molecular classification of HCC based on metabolic zonation: Letter to the editor on Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathwa

Author:Xie, Yongzhi; Zhu, Xiangyu; Liang, Qi

Journal: CLINICAL AND MOLECULAR HEPATOLOGY. 2026; Vol. 32, Issue 2, pp. e144-e145. DOI: 10.3350/cmh.2025.0610

7
Sex-specific trends and demographic vs. epidemiologic drivers of alcohol-related cirrhosis in United States, 2021-2040: Letter to the editor on Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United State

Author:Wang, Kui; Zeng, Yunqing

Journal: CLINICAL AND MOLECULAR HEPATOLOGY. 2026; Vol. 32, Issue 2, pp. e155-e157. DOI: 10.3350/cmh.2025.0790

8
Hepatitis B in Africa: Progress toward World Health Organization 2030 targets, persistent disparities, and COVID-19 setback

Author:Wang, Kui; Zhou, Ruchen

Journal: CLINICAL AND MOLECULAR HEPATOLOGY. 2026; Vol. 32, Issue 2, pp. e211-e215. DOI: 10.3350/cmh.2026.0151

9
Correspondence to letter to the editor on Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosi

Author:Wang, Haiyu; Chen, Jinjun

Journal: CLINICAL AND MOLECULAR HEPATOLOGY. 2026; Vol. 32, Issue 2, pp. e238-e240. DOI: 10.3350/cmh.2025.0611

10
Letter to the editor on Glucagon-like peptide 1 receptoragonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation stud

Author:Wang, Chunyan; Han, Xu; Li, Yinyan

Journal: CLINICAL AND MOLECULAR HEPATOLOGY. 2026; Vol. 32, Issue 2, pp. e167-e169. DOI: 10.3350/cmh.2025.0676


在线咨询

Clinical And Molecular Hepatology

国际简称:CLIN MOL HEPATOL参考译名:临床和分子肝病学

年发文量:84 CiteScore:28.1 是否预警:否 Gold OA文章占比:100.00% 研究类文章占比:61.90%

杂志社联系方式:RM A1210, 53 MAPO-DAERO, MAPOTRAPALACE, DOWHA-DONG, MAPO-GU, SEOUL, SOUTH KOREA, 04158

Clinical And Molecular Hepatology